Q-omics provides the consensus-scored RPS16P5 profile across patient tissues and cancer cell-line models. RPS16P5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPS16P5 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, RPS16P5 RNA expression shows 11,582 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, THCA, and THYM as cancer lineages where RPS16P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS16P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS16P5 survival associations across molecular data types. RPS16P5 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS16P5 RNA expression–survival associations across cancer types. High RPS16P5 expression shows unfavorable associations in COAD and KICH, but favorable associations in CESC, BRCA, SKCM and LUAD. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for RPS16P5 RNA expression.
This table summarizes RPS16P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS16P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS16P5 shows lower tumor expression in THCA and higher tumor expression in KIRC, LUAD and CHOL. The THCA box plot shows higher RPS16P5 RNA expression in normal versus tumor tissue (log2 FC = −0.450, t-test p < 0.001).
This table shows molecular features associated with RPS16P5 in patient tissues and cancer cell lines. In patient samples, RPS16P5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
